Companies: 10,795·Total market cap: $144.5T
Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

ESLANASDAQHealthcare● Active
$1.13
$-0.01(-0.88%)
Market Cap$48628646
P/E Ratio—
52W High$3.15
52W Low$0.78
SEC Filings

Estrella Immunopharma, Inc. (ESLA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001844417 · ESLA · NASDAQ · as of Jun 9, 2026

Filing snapshot

246
Total Filings
DEF 14A
Latest Form
2026-05-27
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001844417 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-30
Fiscal Year End
Apr 30, 2026
Accession No.
0001213900-26-050433
Primary Document
ea0288591-10ka1_estrella.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001844417 · Accession 0001213900-26-050433

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-18
View 10-Q on SEC
8-KCurrent Report
CURREN REPORT
2026-01-13Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
DEF 14AProxy Statement
DEF 14A
2026-05-27
View
10-QQuarterly Report
QUARTERLY REPORT
2026-05-18
View
NT 10-QNT 10-Q
NOTIFICATION OF LATE FILING
2026-05-18
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
10-K/AAnnual Report (Amended)
AMENDMENT NO. 1 TO FORM 10-K
2026-04-30
View
10-KAnnual Report
ANNUAL REPORT
2026-03-18
View
424B3424B3
PROSPECTUS
2026-02-13
View
EFFECTEFFECT
EFFECT
2026-01-23
View
S-1/AS-1/A
REGISTRATION STATEMENT
2026-01-22
View
S-1/AS-1/A
REGISTRATION STATEMENT
2026-01-16
View
8-KCurrent Report
CURREN REPORT
2026-01-13
View
8-KCurrent Report
CURRENT REPORT
2026-01-06
View
424B5424B5
PROSPECTUS SUPPLEMENT
2026-01-06
View
S-1IPO Registration Statement
REGISTRATION STATEMENT
2025-12-22
View
8-KCurrent Report
CURRENT REPORT
2025-12-04
View
Showing 1–15 of 234 filingsForm 4 / 144 hidden· 246 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001844417  |  Exchange: NASDAQ · Healthcare

Estrella Immunopharma, Inc. (NASDAQ: ESLA) has submitted 246 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001844417, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Estrella Immunopharma, Inc.'s most comprehensive regulatory disclosure. The most recent Estrella Immunopharma, Inc. 10-K was filed on 2026-04-30 for fiscal year ending 2026. Historical ESLA 10-K annual reports are available from 2021 through 2026.

Investors researching Estrella Immunopharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
IMMX SEC Filings →GLSI SEC Filings →SRZN SEC Filings →ONCY SEC Filings →EXOZ SEC Filings →TLSA SEC Filings →TIL SEC Filings →TVGN SEC Filings →
→ ESLA Financials→ ESLA Earnings→ ESLA Insider Trades

Frequently Asked Questions

ESLA SEC Filings · 8 questions

Estrella Immunopharma, Inc. (ESLA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 246 filings and access original documents at no cost. Estrella Immunopharma, Inc.'s CIK is 0001844417.

ESLA SEC filingsEstrella Immunopharma, Inc. SEC documentsfind ESLA 10-K